Immunogenicity of biologic therapies for migraine: a review of current evidence

BACKGROUND: Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have been shown to be effective in migraine prevention. Eptinezumab, erenumab, fremanezumab, and galcanezumb have shown efficacy in clinical trials along with favorable safety and tolerability profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Joshua M., Ning, Xiaoping, Kessler, Yoel, Rasamoelisolo, Michele, Campos, Verena Ramirez, Seminerio, Michael J., Krasenbaum, Lynda J., Shen, Honglue, Stratton, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791637/
https://www.ncbi.nlm.nih.gov/pubmed/33413094
http://dx.doi.org/10.1186/s10194-020-01211-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791637/
https://www.ncbi.nlm.nih.gov/pubmed/33413094
http://dx.doi.org/10.1186/s10194-020-01211-5

Ejemplares similares